Related Experiment Video
Updated: Mar 30, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Effects of interleukin 10 polymorphisms on the development of hepatitis B virus infection: a systemic review and
Chi Shu1, Jiarong Wang1, Yazhou He2
1West China School of Medicine, Sichuan University Chengdu, Sichuan Province, China.
Abstract:
Current opinion varies in the roles of the IL-10 polymorphisms in the process of hepatitis B virus (HBV) infection. We have performed a systemic review and up-dated meta-analysis including 37 eligible case-control studies to summarize all the available data on the association between IL-10 polymorphisms and development of HBV infection. In the present study, we found that the IL-10-1082 G/A, -592 C/A polymorphisms were associated with a significantly decreased risk of chronic HBV infection (AA + GA vs. GG: P = 0.003, OR = 0.55, 95% CI = 0.37-0.82; AA vs. CA + CC: P = 0.03, OR = 0.83, 95% CI = 0.71-0.98). While the -819 C/T TT carriers were associated with a borderline significantly decreased risk of chronic HBV infection (TT vs. CT + CC: P = 0.05, OR = 0.82, 95% CI = 0.68-1.00). Significant result was observed in the association between IL-10-1082 G/A polymorphism and HBV clearance (AA vs. GG: P = 0.04, OR = 1.33, 95% CI = 1.01-1.75). In addition, significant association was found between the -1082 G/A, -819 C/T polymorphisms and an increased risk of progression of HBV infection from asymptomatic carrier to chronic hepatitis B (AA + GA vs. GG: P = 0.0003, OR = 2.13, 95% CI = 1.41-3.22; TT + CT vs. CC: P = 0.005, OR = 1.53, 95% CI = 1.13-2.07), whereas the -592 C/A polymorphism was associated with a significantly decreased risk of progression from asymptomatic carrier to hepatocellular carcinoma (AA vs. CC: P = 0.02, OR = 0.63, 95% CI = 0.43-0.92). Our meta-analysis suggested that the IL-10 polymorphisms might be associated with a decreased risk of chronic HBV infection, while the -1082 AA carriers might be more likely to clear HBV following acute infection. In addition, these three polymorphisms might cast in roles of the progression of HBV infection.
More Related Videos
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Inhibitors of Viral Protein Synthesis
Hepatitis
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

